Book ChapterDOI
Eyelid and Periocular Skin Tumors
Maria Kirzhner,Zeynel A. Karcioglu +1 more
- pp 259-276
TLDR
Orbital invasion from eyelid tumors usually results from a delayed presentation/diagnosis, incomplete treatment with subsequent recurrences, and highly aggressive invasive tumors.Abstract:
Malignant skin neoplasias commonly affect the eyelids and periocular region, particularly in high UV exposure zones. Secondary orbital invasion is a serious and potentially fatal complication of cutaneous tumors. The most frequent skin tumors resulting in orbital invasion are basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanomas. Orbital invasion from eyelid tumors usually results from a delayed presentation/diagnosis, incomplete treatment with subsequent recurrences, and highly aggressive invasive tumors.read more
Citations
More filters
Journal Article
Orbital exenteration with spontaneous granulation
TL;DR: In this article, spontaneous granulation tissue has been used to allow the orbit to heal spontaneously with granulation tissues, which has several advantages over the popular technique of lining the orbital walls with a split-thickness skin graft.
Journal ArticleDOI
Review of Targeted Therapies for Periocular Tumors.
TL;DR: Common eyelid and periocular malignancies are discussed, as well as novel-targeted therapies to treat these cancers.
References
More filters
Journal ArticleDOI
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.
TL;DR: The depth of invasion was studied using the criteria for staging of Clark et al.2 to see if maximal cross-sectional area, thickness, stage of invasion, or a combination of these can be of value in assessing the prognosis of cutaneous melanoma.
Journal Article
The Histogenesis and Biologic Behavior of Primary Human Malignant Melanomas of the Skin
TL;DR: Evidence is presented suggesting that superficial spreading melanoma and lentigo maligna melanoma (Hutchinson9s melanotic freckle) show a long period of superficial growth, followed by the relatively rapid appearance of nodules or deeper invasion within the primary lesion.
Journal ArticleDOI
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulic,Michael R. Migden,Anthony E. Oro,Luc Dirix,Karl D. Lewis,John D. Hainsworth,James A. Solomon,Simon Yoo,Sarah T. Arron,Philip Friedlander,Philip Friedlander,Ellen S. Marmur,Charles M. Rudin,Anne Lynn S. Chang,Jennifer A. Low,Howard Mackey,Robert L. Yauch,Richard A. Graham,Josina C. Reddy,Axel Hauschild +19 more
TL;DR: A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma.
Journal ArticleDOI
Management of cutaneous melanoma.
TL;DR: The authors of this review discuss the pathogenesis and management of cutaneous melanoma and provide perspective on treatment options.
Journal ArticleDOI
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
Jean Y. Tang,Julian Mackay-Wiggan,Michelle Aszterbaum,Robert L. Yauch,Joselyn Lindgren,Kris S. Chang,Carol Coppola,Anita M. Chanana,Jackleen Marji,David R. Bickers,Ervin H. Epstein +10 more
TL;DR: Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal- cell carcinomas in patients with the basal -cell nevus syndrome and the adverse events associated with treatment led to discontinuation in over half of treated patients.